{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:40:24Z","timestamp":1715596824761},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1157\/13126215","type":"journal-article","created":{"date-parts":[[2008,10,23]],"date-time":"2008-10-23T06:17:51Z","timestamp":1224742671000},"page":"406-411","source":"Crossref","is-referenced-by-count":9,"title":["Respuesta antihipertensiva a la espironolactona en pacientes con hipertensi\u00f3n arterial refractaria"],"prefix":"10.1016","volume":"131","author":[{"given":"Enrique","family":"Rodilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"P\u00e9rez-Lahiguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13126215_bb0005","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1157\/13126215_bb0010","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","year":"2007","journal-title":"J Hypertens"},{"key":"10.1157\/13126215_bb0015","doi-asserted-by":"crossref","unstructured":"ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:1981-97 [fe de errores: JAMA. 2003; 289:178; 2004;291:2196].","DOI":"10.1001\/jama.288.23.2981"},{"key":"10.1157\/13126215_bb0020","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1157\/13126215_bb0025","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1157\/13126215_bb0030","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/01.hjh.0000174968.72212.ac","article-title":"Resistant hypertension","volume":"23","author":"Kaplan","year":"2005","journal-title":"J Hypertens"},{"issue":"1 Suppl 1","key":"10.1157\/13126215_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1524-6175.2007.6106.x","article-title":"Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis","volume":"9","author":"Park","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1157\/13126215_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1074248406289735","article-title":"Resistant hypertension: diagnosis and management","volume":"11","author":"Papadopoulos","year":"2006","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1157\/13126215_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMcp041698","article-title":"Clinical practice. Resistant or difficult-to-control hipertensi\u00f3n","volume":"355","author":"Moser","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13126215_bb0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11906-005-0064-6","article-title":"Treatment of resistant hypertension","volume":"7","author":"Taler","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"10.1157\/13126215_bb0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1157\/13126215_bb0060","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1157\/13126215_bb0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1157\/13126215_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1524-6175.2007.06334.x","article-title":"Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension","volume":"9","author":"Calhoun","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1157\/13126215_bb0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/bmj.293.6547.611","article-title":"Recommendations on blood pressure measurement","volume":"293","author":"Petrie","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1157\/13126215_bb0080","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1157\/13126215_bb0085","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1157\/13126215_bb0090","first-page":"5","article-title":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1157\/13126215_bb0095","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1157\/13126215_bb0100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"key":"10.1157\/13126215_bb0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"10.1157\/13126215_bb0110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"10.1157\/13126215_bb0115","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1157\/13075846","article-title":"Hiperaldosteronismo primario: an\u00e1lisis de una serie de 54 pacientes","volume":"124","author":"Sabio","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13126215_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","article-title":"High incidence of primary hyperal dosteronism in 199 patients referred with hypertension","volume":"21","author":"Gordon","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1157\/13126215_bb0125","first-page":"1863","article-title":"Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology","volume":"85","author":"Fardella","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13126215_bb0130","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/clinchem\/48.11.1919","article-title":"Screening for primary aldosteronism: implications of an increased plasma aldosterone\/renin ratio","volume":"48","author":"Schwartz","year":"2002","journal-title":"Clin Chem"},{"key":"10.1157\/13126215_bb0135","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/00004872-200405000-00001","article-title":"The current epidemic of primary aldosteronism: causes and consequences","volume":"22","author":"Kaplan","year":"2004","journal-title":"J Hypertens"},{"key":"10.1157\/13126215_bb0140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/eje.0.1510305","article-title":"Would wider screening for primary aldosteronism give any health benefits?","volume":"151","author":"Plouin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1157\/13126215_bb0145","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","article-title":"Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells","volume":"269","author":"Hatakyama","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1157\/13126215_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1157\/13126215_bb0155","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1157\/13126215_bb0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0039-128X(96)00010-4","article-title":"Mineralocorticoids, salt and high blood pressure","volume":"61","author":"G\u00f3mez-S\u00e1nchez","year":"1996","journal-title":"Steroids"},{"key":"10.1157\/13126215_bb0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00129784-200707010-00007","article-title":"Aldosterone antagonists: the most underutilized class of heart failure medications","volume":"7","author":"Guglin","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1157\/13126215_bb0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00129784-200505010-00007","article-title":"Eplerenone: a review of its use in essential hypertension","volume":"5","author":"Croom","year":"2005","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1157\/13126215_bb0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1157\/13076402","article-title":"Sociedad Espa\u00f1ola de Hipertensi\u00f3n-Liga Espa\u00f1ola para la Lucha contra la Hipertensi\u00f3n Arterial (SEH-LELHA) Gu\u00eda sobre el diagn\u00f3stico y tratamiento de la hipertensi\u00f3n arterial en Espa\u00f1a 2005","volume":"125","author":"Mar\u00edn","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13126215_bb0180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1157\/13086047","article-title":"Efectos de la administraci\u00f3n temporalizada de f\u00e1rmacos antihipertensivos en pacientes con hipertensi\u00f3n arterial resistente","volume":"126","author":"Calvo","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13126215_bb0185","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1097\/01.hjh.0000249707.36393.02","article-title":"Determinants of urinary albumin excretion reduction in essential hypertension: a long-term follow-up study","volume":"24","author":"Pascual","year":"2006","journal-title":"J Hypertens"},{"key":"10.1157\/13126215_bb0190","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/01.HYP.0000167151.52825.11","article-title":"Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension","volume":"45","author":"Pascual","year":"2005","journal-title":"Hypertension"},{"key":"10.1157\/13126215_bb0195","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.HYP.31.2.712","article-title":"Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study","volume":"31","author":"Redon","year":"1998","journal-title":"Hypertension"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308724345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308724345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T08:15:39Z","timestamp":1632039339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775308724345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0025775308724345"],"URL":"https:\/\/doi.org\/10.1157\/13126215","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}